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Abstract: Currently, AIDS or severe immunodeficiency remains as a challenge for people with 
HIV (PWHIV) and healthcare providers. Our purpose was to analyze the impact of advanced HIV 
disease (AHD) on mortality, life expectancy and health-related quality of life (HRQoL). We re-
viewed cohort studies and meta-analyses conducted in middle- and high-income countries. To an-
alyze HRQoL, we selected studies that reported overall health and/or physical/mental health 
scores on a validated HRQoL instrument. AIDS diagnosis supposes a higher risk of mortality dur-
ing the first six months, remaining higher for 48 months. It has been reported that cancer and car-
diovascular disease persist as frequent causes of mortality in PWHIV, especially those with previ-
ous or current AHD. PWHIV who initiate combination antiretroviral therapy (cART) with CD4 < 
200 cells/µL have significantly lower estimated life expectancy than those with higher counts. 
AHD is associated with lower HRQoL, and a worse physical health or mental health status. AIDS 
and non-AIDS defining events are significant predictors of a lower HRQoL, especially physical 
health status. AHD survivors are in risk of mortality and serious comorbidities, needing special 
clinical attention and preventive programs for associated comorbidities. Their specific needs 
should be reflected in HIV guidelines. 
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1. Introduction 
In the early years of the human immunodeficiency virus (HIV) pandemic, acquired 
immunodeficiency syndrome (AIDS) was a fatal condition accompanied by severe op-
portunistic diseases, with physical symptoms such as wasting, diarrhea, fever, and a 
short-time mortality. In addition, people living with HIV (PWHIV) suffered social isola-
tion, internalized stigma, problems related to drug abuse, depression, anxiety, and other 
psychosocial conditions [1]. With the advent of high-activity antiretroviral therapy 
(HAART) in 1996, AIDS mortality decreased dramatically, although serious adverse 
events secondary to the new antiretroviral drugs began to surface. The HIV population 
who survived to AIDS, known as long-term survivors [2], frequently suffer a constella-
tion of medical, psychological, and emotional disorders, and low quality of life related to 
health (HRQoL) [3,4]. 
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Despite improvements in early HIV diagnosis and global efforts to deliver combina-
tion antiretroviral therapy (cART), many patients are still at risk of advanced HIV disease 
(AHD). The Joint United Nations Program on HIV/AIDS (UNAIDS) reported that at the 
end of 2018, around 770,000 (uncertainty bounds, 570,000–1.1 million) people died from 
AIDS-related illnesses worldwide [5]. In 2017, the European Centre for Disease Control 
reported 3,130 AIDS diagnoses in the 28 European Union/European Economic Ar-
ea(EU/EEA) countries, giving a crude rate of 0.7 cases per 100,000 of the population [6]. 
AHD continues to have a negative impact among some PWHIV, despite antiretrovi-
ral therapy [7]. Currently, surviving to AHD can be a real challenge for some PWHIV 
and their healthcare providers. Our aim is to review the impact of AHD on mortality 
and HRQoL in PWHIV living in countries with easy access to cART. 
2. Methodology 
Our population of interest was people diagnosed with AHD. We used the stage 3 
definition of HIV disease from the Centers for Disease Control and Prevention (CDC), 
which includes those PWHIV with AIDS or CD4 < 200 cells/µL [8]. For the objectives of 
this article, we reviewed the scientific literature in PubMed and Google Scholar in Eng-
lish language journals before July 2020, with the condition that most of the study should 
have been carried out during the 21st century and started after the availability of 
HAART (1996). We selected cohort studies and meta-analyses conducted in middle- and 
high-income countries with universal access to cART and to healthcare. To identify in-
dependent determinants of mortality, loss of life expectancy, and perceived HRQoL, ar-
ticles had to report appropriate statistics, especially a multivariate regression analysis on 
the association between AHD and the corresponding endpoint variables. Moreover, to 
analyze HRQoL, we selected cross-sectional and longitudinal studies that reported over-
all health and/or physical/mental health scores on a validated HRQoL instrument. 
We searched for the terms “mortality”, “life expectancy”, “cancer”, “cardiovascular 
disease” and “health-related quality of life”. Each term was crossed with “AIDS diagno-
sis” or “advanced HIV disease” or “CD4 cells”. 
The main reasons to exclude articles were: (1) did not strictly comply with inclusion 
criteria; (2) did not include patients with AHD or CD4+ lymphocyte counts below 
200/µL; and (3) did not include multivariable analysis about the subject of researching. 
We decided not to review liver disease due to hepatitis C virus (HCV), because the cur-
rently available high-active antiviral agents against HCV are decreasing the incidence, 
morbidity and mortality of serious liver disease in PWHIV. 
3. Results 
3.1. Factors Associated to AHD or Progression to AIDS 
Studies conducted in high-income countries showed that the populations most like-
ly to present for care with AHD are men, heterosexuals, older people, people who inject 
drugs, migrants, people suffering socioeconomic inequalities, and people with lower 
educational levels [9,10]. 
Factors associated with progression to AHD are social (previous incarceration, non-
continuity in HIV care) and immunovirological outcomes (low CD4+ count, poor CD4+ 
response to therapy, drug resistance). The adjusted risk for progression to AIDS associ-
ated with a poor CD4+ recovery (discordant immunovirological response to treatment) 
was as high as 2.70 (95% CI 1.29–5.66) in some studies [11–14]. 
3.2. Life Expectancy and Mortality in AHD Patients 
Life expectancy in PWHIV on cART has improved worldwide, but an important 
gap remains compared with the general population [15]. PWHIV at higher risk of mor-
tality in Western countries include people who inject drugs, people living in resource-
constrained settings, and people who are highly stigmatized or who face other barriers 
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such as depression and other mental disorders, access to health services, unemployment, 
family responsibilities, and so on [5,11,15,16]. 
In our review, we included 14 studies (Table 1): three analyzed life expectancy, and 
11 explored mortality associated with AIDS defining-events (ADEs) and non-AIDS de-
fining-events (NADEs). All of them were cohort studies and were mainly conducted in 
high-income Western countries (Europe and North America), but one included patients 
from Israel and Argentina. 
Cohort studies are quite homogeneous in this regard. Results from longitudinal co-
hort studies published during the 21st century demonstrate that even on cART, patients 
with AHD have an increased risk of mortality related with AIDS and non-AIDS events. 
PWHIV who initiate cART with CD4 < 200 cells/µL have significantly lower estimated 
life expectancies [16–18] and a higher risk of mortality by ADEs and NADEs than those 
with higher counts [19–22]. Patients presenting for care with AIDS have a higher risk of 
mortality during the first six months, and it persists higher during the 48 months after 
AIDS diagnosis compared with those without previous AIDS [23,24]. After surviving 
five years with cART, the mortality of patients who started cART with a  low baseline 
CD4 count converged with mortality of patients with intermediate and high baseline 
CD4 counts [25]. In addition, most of the cohort studies agree that starting cART with 
higher CD4 counts decrease mortality in PWHIV [26–29]. These results are independents 
of gender, age, and type or number of comorbidities (Table 1). 
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Population Study Period Impact of Advanced HIV Disease on Mortality and Life Expectancy 







• Expected age at death (years) in 20-year-olds with CD4 count < 100 cells/µL, 100–199 
cells/µL and ≥ 200 cells/µL: 32.4 (SE, 1.1), 42.0 (0.62) and 50.4 (0.41), respectively. 
May [18] Cohort study 
(UK-CHIC) 
United Kingdom 2000–2010 
• Expected age at death (years) at the start of ART in 35-year-olds with CD4 count ≤ 200 
cells/µL and 200–349 cells/µL: 71 (95% CI, 68–73) and 78 (74–82), respectively. 
• Expected age of death (years) after 5 years on ART in 35-year-olds with CD4 count < 200 
cells/µL and no viral suppression, and CD4 count ≥ 350 cells/µL and viral suppression: 
54 (95% CI, 48–61) and 80 (76–83), respectively. 




United States 2009 *  
• Life expectancy in years from age 33 (and additional years lost compared to starting 
ART with CD4 count ≥ 200 cells/μL) in patients with CD4 count ≤ 200 cells/μL and <50 
cells/µL: 18.75 (3.90) and 13.82 (8.83), respectively. 





• Risk of death, expressed in aHR (95% CI), in patients presenting with AIDS during first 6 
months of follow-up and during months 12 to 48 was 48.3 (28.0–83.5) and 4.8 (3.3–7.0), 
respectively. 
• Corresponding values among AIDS-free patients with CD4 count ≤ 200 cells/µL were 8.1 
(4.5–14.6) and 2.3 (1.6–3.4). 
Mocroft [23] 
 Cohort study 
(COHERE) Europe 2000–2011 
• Increased rate of AIDS/death beyond two years after diagnosis in people presenting for 
care with AHD in southern Europe (aIRR, 1.38; 95% CI, 1.01–1.88) and in eastern Europe 
in the first year (aIRR, 6.98; 95% CI, 4.22–11.56). 
Mortality associated with CD4 count 
Baker [26] Cohort study U.S.A. 1999–2005 
• Reduction (%) in risk resulting from each increase of 100 cell/µL in CD4 count was 44% 
(95% CI for HR, 0.50–0.62) for AIDS; 14% (0.77–0.96) for NADEs; 35% (0.59–0.72) for 






• Reduction (%) in risk resulting from each increment of 100 cells/µL in the CD4 count was 
32% (95% CI, 28–35) for all-cause mortality; 64% (58–69) for ADEs; 33% (18–46) for end-








• Reduction in risk due to doubling of CD4 count, represented by adjusted IRR (95% CI), 
was 0.63 (0.60–0.66) for ADEs; 0.80 (0.75–0.85) for NADEs, 0.78 (0.69–0.87) for NADC; 
0.70 (0.57–0.80) for ESRD; 0.73 (0.65–0.83) for liver-related events. The reduction in risk 
of cardiovascular events was not significant (IRR, 0.98; 95% CI, 0.85–1.12). 
Young [29] 
Cohort study 
(COHERE) Europe 1997–2010 
• HR for new AIDS event or death in people with CD4 < 200/µ/L, 200–350/µ/L and 350–
500/µL was 0.35 (95% CI, 0.30–0.40), 0.74 (0.66–0.83) and 0.96 (0.92–0.99), respectively. 






• Adjusting for other prognostic factors and comparing baseline CD4 < 50 cells/µL with 
200–349 cells/µL during the first 6 months of ART, MRR was 2.81 (95% CI, 2.12–3.71), 
declining to 1.59 (1.31–1.92) 3 to 4.9 years after the start of ART. 







• aHR for all-cause mortality in people with CD4 count ≤ 200 cells/μL without AIDS and 
people with AIDS was 5.6 (95% CI, 2.7–11.9) and 22.6 (11.5–44.6), respectively. 
Ingle [22] Cohort study  Europe/U.S.A. 2014 * 
• CD4 count at death was lowest for those who died of AIDS-related causes, with a medi-
an of 48 cells/µL (IQR, 13–140), and highest for those who died of CVD (360; 221–608) 
and unnatural causes (340; 150–560). 
Mortality associated with NADEs 
Zhang [19] 
Cohort study  
(ATHENA) Netherlands 1998–2012 
• RR of composite non-AIDS-related endpoint (major CVDs, liver fibrosis/cirrhosis, and 
non-AIDS-related malignancies) was 4.71 (95% CI, 2.98–7.45) for people with CD4 count 
< 200 cells/µL, vs. 1.19 (0.82–1.74) for people with CD4 of 350–499 cells/µL; and 2.89 
(1.79–4.64) for those with a CDC-C event vs. 1.98 (1.23–3.20) for those with a CDC-B 
event. 




• Risk of overall non-AIDS mortality was higher in patients with vs. without ADE (aHR, 
2.21; 95% CI, 2.00–2.43). 
* year of publication. ADE: AIDS-defining event; aHR: adjusted hazard ratio; aIRR: adjusted incidence rate ratio; ART: 
antiretroviral therapy; cART: combination antiretroviral therapy; CDC: Centers for Disease Control and Prevention; cHR 
crude hazard ratio; CI: confidence interval; CVD: cardiovascular disease; ESRD: end-stage renal disease; HR: hazard ra-
tio; IQR: interquartile range; IRR: incidence rate ratio; MHR: mortality hazard ratio; MRR: mortality rate ratio; NADC: 
non-AIDS defining cancer;  NADE: non-AIDS-defining event; RR: relative risk; SE: standard error. 
3.3. Cancer Incidence and Related Mortality in PWHIV with AHD 
Excess of mortality in PWHIV, comparing with the general population of the same 
sex and age, has been observed in non-AIDS cancer, cardiovascular disease, respiratory 
diseases, liver diseases, drug abuse, suicide, and other external causes [15]. The more 
frequent NADEs driving to mortality with previous AIDS or <200 CD4/µL are malig-
nancies, cardiovascular and end-stage liver disease [19,27,28] (Table 1). 
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Cancers in PWHIV are classified as either AIDS-defining cancers (ADC) or non-
AIDS defining cancers (NADC) that includes those related to virus infections (NADCI). 
We analyzed eight studies on the impact of AHD on cancer development; five were 
large cohort studies, two were extracted from a Cancer National Registry, and one was a 
meta-analysis. All of them separately analyzed ADC and NADC in people with previous 
AIDS or CD4 < 200/cells/µL. Data from these studies demonstrate the strong association 
between AHD and increased cancer risk in PWHIV (Table 2). 
Table 2. Impact of advanced HIV disease on cancer incidence. 
Reference Design 
(Cohort Name) 
Population Study Period Impact of Advanced HIV Disease on Cancer Incidence 
Bedimo [34]  Cancer Registry 
(U.S. Veterans-Affairs) 
U.S.A. 1997–2004. 
• Median CD4 counts (cells/µL) were significantly lower for PWHIV with 
NADC (249 vs. 270); anal cancer (156 vs. 270); and Hodgkin lymphoma 
(217 vs. 269), compared to PWHIV without cancer. 
Clifford [30] 
Cohort study  
(SHCS) 
Switzerland 2005 * 
• In PWHIV with CD4 count < 100 cells/µL, SIR was 571 (95% CI, 449–716) 
for KS and 145 (104–197) for NHL. 
• SIR was 25.7 (95% CI, 9.2–56.2) for HL in PWHIV after AIDS diagnosis and 
14.9 (7.7–26.1) before diagnosis. 






• In HIV-infected people with lower recent CD4 counts vs. non-infected 
people, there were higher RRs for KS (p < 0.001), NHL (p < 0.001), HL (p < 
0.001), anal cancer (p = 0.005) and colorectal cancer (p = 0.028). 
• RR in HIV-infected people with CD4 count < 200 cells/µL vs. noninfected 
people was 91.5 (95% CI, 48.0–174.5) for anal cancer and 55.3 (31.3–97.9) for 
HL. 
• For lung, colorectal and oral cavity/pharynx cancer, RRs were only elevat-
ed for HIV-infected individuals with CD4 count < 200 cells/µL. 
Chiu [32]  
Cancer Registry (British 
Columbia)  Canada 1996–2008 
• Independent factors against the development of NADC include the use of 
triple cART compared to mono-/dual-ART (aOR, 0.64; 95% CI, 0.43–0.95); 
and higher nadir CD4 counts (aOR, 0.61; 95% CI, 0.41–0.93 for CD4 count ≥ 
200 cells/µL). 
Kesselring [37] Cohort study 
(ATHENA) 
Netherlands 1996–2009 
• Cumulative exposure to CD4 count < 200 cells/µL results in higher risk of 
NADC (HR, 1.12; range, 1.03–1.22 for each additional year of exposure).  
• In stratified analyses, cumulative exposure to CD4 count < 200 cells/µL 
was associated with malignancies caused by infections (HR 1.16; range 
1.03–1.31) but not with other types of cancers. 
Patel [35] Cohort Study 
(HOS) 
U.S.A. 1996–2010 
• Factors associated with increased mortality for ADC are lower nadir CD4 
counts and HIV VL ≥ 400 copies/mL, with respective HRs of 3.02 (95% CI, 
1.39–6.59) and 1.72 (1.01–2.94). 
• Factors associated with increased mortality for NADCNI are lower nadir 
CD4 counts and detectable HIV VL, with respective HRs of 1.77 (95% CI, 
1.07–2.94) and 1.96 (1.18–3.24). 
Shiels [36] Meta-analysis Multi-site 2007–2009 
• Cancer incidence in patients with previous AIDS diagnosis compared with 
those with non-AIDS, expressed as SIR (95% CI), was 8.02 (3.52–18.25) for 
leukemia, 2.77 (1.43–5.37) for HL, 3.01 (1.69–5.38) for lung cancer, and 3.17 
(1.42–7.09) for all cancers combined. 
Prosperi [33] 
Cohort study 
(ICONA) Italy 2010 * 
• Adjusted RH for ADC and NADC, respectively, by CD4 count: 
o ≤ 50 cells/μL: 20.27 (95% CI, 11.95–34.37; p < 0.001) and 2.44 (95% CI, 
0.76–7.83; p = 0.1)  
o 50–200 cells/µL: 6.48 (95% CI, 3.98-10.57; p < 0.001 and 2.76 (95% CI, 
1.35–5.65; p = 0,006) 
o 200–350 cells/µL: 1.73 (95% CI, 0.99-3.04; p = 0.054) and 1.69 (95% CI, 
0.9–3.2; p = 0.1) 
* Year of publication. ADC: AIDS-defining cancer; aOR: adjusted odds ratio; cART: combined antiretroviral therapy; CI: 
confidence interval; HL: Hodgkin lymphoma; HR: hazard ratio; KS: Kaposi sarcoma; NADC: non-AIDS-defining cancer; 
NADCNI: non-AIDS-defining noninfection-related cancer; NHL: non-Hodgkin lymphoma; PWHIV: people living with 
HIV; RR: relative risk; SIR: standardized incidence ratio; VL: viral load. 
Low CD4 cell count is an independent predictor of developing ADC and NADCI: 
Kaposi sarcoma, non-Hodgkin lymphoma [30–33], anal cancer and Hodgkin lymphoma 
[34–37]. Data from the ATHENA cohort associate cumulative exposure to CD4 < 200 
cells/µl during cART with increased risk of NADCI [37]. Previous AIDS diagnosis is also 
a risk factor of cancer, compared with those with non-AIDS [36]. Results on the associa-
tion between AHD and NADC are discordant (Table 2). Some studies show an associa-
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tion between AHD and lung cancer, colorectal and oral cavity/pharynx cancer [31,35], 
while other studies find no associations [30]. 
Regarding mortality, Patel et al. [35] from the HIV Outpatient Study (HOPS) cohort 
reported that factors associated with all-cause mortality among persons with ADC were 
a nadir CD4 cell count < 200 cells/mm3 and HIV RNA ≥ 400 copies/mL. Among persons 
with NADCI, no associated factors were identified. Among persons with NADC, factors 
associated with increased mortality were older age at cancer diagnosis, non-white race, 
nadir CD4 cell count < 200 cells/mm3, viral load ≥ 400 copies/mL, and prior or current 
history of tobacco use. 
3.4. Cardiovascular Disease-Related Mortality in PWHIV with AHD 
The effect of AHD on the pathogenesis of cardiovascular disease (CVD) is not well 
established. Traditional cardiovascular risk factors seem to play the main role in this 
condition. However, some data suggest that AHD may influence the incidence and out-
come of CVD and strokes. Authors from the NA-ACCORD cohort analyzed the inci-
dence of type 1 (atherothrombotic) myocardial infarction (T1MI) and risk attributable to 
traditional and HIV-specific factors. The multivariable analysis showed that lower CD4 
counts were significatively associated with higher risk T1MI. The adjusted incidence rate 
ratios (aIRR) for CD4 counts < 100 cells/µL were: 2.19 (95% CI: 1.44–3.33); 100–199 
cells/µL: 1.60 (95% CI: 1.09–2.34); and 200–349 cells/µL: 1.37 (95% CI: 1.01–1.86) [38]. In a 
systematic review and meta-analysis, Eyawo et al. [39] found that CD4 count < 200 
cells/µL was associated with higher MI risk compared with ≥200 cells/μL in three studies 
and HIV VL ≥ 100,000 copies/mL was associated with increased MI risk compared with 
<100,000 copies/mL in two studies. However, Feinstein et al. reported that significant 
mortality predictors for T1MI in PWHIV were only high HIV viral load (HIV-VL), renal 
dysfunction, and older age; and for a type 2 (supply-demand mismatch) MI, low body-
mass index and detectable HIV [40]. 
In a nationwide inpatient sample from the United States, PWHIV with previous 
AIDS were significantly more likely than uninfected patients to die during hospitaliza-
tion after admission for MI (OR: 3.03; 95% CI, 1.71–5.38), or stroke (OR: 2.59; 95% CI, 
1.97–3.4) [41]. In the same way, in a retrospective cohort study about the outcomes of MI 
and cardiogenic shock in PWHIV, AIDS was also associated with higher in-hospital 
mortality compared with HIV people without previous AIDS (28.8% vs. 21.1%; aOR: 4.12 
[95%CI: 1.89–9.00]) [42]. 
The authors of a Taiwanese study reported cytomegalovirus end-organ disease as 
an independent risk factor for incident all-cause stroke, and particularly ischemic stroke, 
in PWHIV [43]. Lastly, data from a meta-analysis including 724 cases of intracerebral 
hemorrhage linked AIDS diagnosis and low CD4 with higher incidence of this event 
[44]. 
All these data suggest the high vulnerability and risk of dying after an AHD diag-
nosis. Mortality related with NADEs could be prevented with the treatment of tradition-
al risk factors such as smoking, elevated total cholesterol, hypertension, and chronic 
HCV infection [45]. Exhaustive screening of traditional risk factors is necessary to reduce 
mortality in PWHIV with previous or current AHD. 
3.5. AHD and Health-Related Quality of Life (Table 3) 
We reviewed 11 articles that analyzed the impact of AHD on HRQoL and that 
complied with the inclusion criteria (Table 3).These articles were heterogeneous, with 
different populations and different study designs. They used a variety in measurement 
tools, including generic and HIV-specific ones. Generic HRQoL measures are those ap-
plicable across types and severities of disease, across different medical treatments or 
health interventions, and demographic and cultural subgroups. Disease-specific 
measures are those that assess specific diagnosis groups or patient populations such as 
PWHIV. Six of the reviewed articles were cross-sectional studies, and five had a longitu-
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dinal design. All studies were conducted in high-income countries, mostly in North 
America. Sample sizes ranged from 744 to 2508 PWHIV in the cross-sectional studies, 
and from 265 to 1000 PWHIV in the longitudinal studies. 
All the studies found an association between CD4 count and HRQoL. Some associ-
ated low CD4 counts with lower overall HRQoL scores or self-perception of health [46–
48], while others linked low CD4 count to worse physical health status [49] or mental 
health status [50,51]. A cross-sectional study using a multidimensional HIV-specific 
HRQoL measure showed that PWHIV with the lowest CD4 counts had the lowest scores 
in several HRQoL domains, including physical health status [48]. Longitudinal studies 
found that lower CD4 count predicted worse physical health status and worse mental 
health status [52–56]. 
Some cross-sectional studies [50,51] and longitudinal studies [52,54,56] found that 
AIDS defining events impaired HRQoL. 
Some studies associate worse HRQoL with other variables that are potentially relat-
ed to HIV disease progression, such as HCV coinfection [46], cART adverse events [50–
52,54] and medical comorbidities (including HIV-related symptoms and non-AIDS 
comorbidities) [49,55,56]. 
In addition to clinical and biological markers, the studies we reviewed consistently 
associated several socio-demographic and psychosocial factors with worse HRQoL in 
PWHIV. These factors included ageing, housing, depression, social support, employ-
ment, and HIV-related stigma. 
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Impact of Advanced HIV Disease on HRQoL 
Other Factors Associated with 
HRQoL  
Cross-sectional studies 
Aden [46]  
(WHIS) 
n = 2508  





• Women with HIV with CD4 count ≤ 200 cells/μL 
2 had lower mean HRQoL scores than women with HIV 
with CD4 > 200 cells/µL and women without HIV (p < 
0.01). 
• Women with HIV with detectable viral load had 
lower HRQoL scores than those with undetectable viral 
load (p < 0.01).  
• In the multivariate analysis, chronic HCV (p < 
0.01), and low CD4 count (p < 0.01) were independently 
associated with lower HRQoL  
• HRQoL scores declined 
with increasing age and de-
creasing level of education.  
• Current use of illicit 
drugs was associated with 
lower HRQoL scores  
Preau [50] 
(ANRS) 
n = 2235 





• Detectable HIV-VL 2 (p = 0.02), AIDS-defining 
events (p = 0.003) and adverse HIV treatment reactions 
(p < 0.0001) were associated with low PHS.  
• Low CD4 cell count 2 (p = 0.0007) and adverse 
HIV treatment reactions (p < 0.0001) were associated 
with low MHS. 
• Low PHS was associat-
ed with older age, absence of a 
stable relationship, and uncom-
fortable housing conditions.  
• Financial difficulties, 
disclosure of HIV status, anxie-
ty and depression, HIV-related 
stigma, and use of illicit drugs 
were associated with both poor 
PHS and MHS.  
Fumaz [51]  
n = 744  







• Variables associated with PHS in men were 
absence of SAEs (p < 0.01) and past OI (p < 0.01); and in 
women, years since HIV diagnosis (p < 0.01), absence of 
SAEs (p < 0.01), and past OI (p < 0.01). 
• Better MHS was related to higher CD4 count 1 (p 
= 0.02) and absence of SAEs (p = 0.04) in women with 
HIV. Men and women coincided in the absence of past 
OI being related to better MHS (p < 0.01).  
• Employment and HIV 
not acquired through the injec-
tion route was related to better 
PHS and MHS in men with 
HIV. 
• Having a stable partner 
was related only to better MHS 
in men. 
Emuren [49]  
(NHS) 
n = 1668 
(median, 40;  





• CD4 count < 200 cells/µL 2 (p < 0.0001), AIDS 
diagnosis (p = 0.0009), and medical comorbidities (p < 
0.0001) were associated with lower PHS.  
• CD4 count < 200 cells/µL 2 (p < 0.05) was associ-
ated with lower MHS.  
• Being married, lower 
military rank and ageing were 
associated with lower PHS.  
• Increasing age and 
being African American were 
associated with higher MHS.  
• Mental comorbidities 
were associated with both 
lower PHS and MHS.  
Fuster [48] 
n = 1462 








• Participants with CD4 count < 200 cells/µL 1 had 
the lowest scores in the following dimensions of 
HRQoL: general health (p < 0.0001), physical health (p = 
0.004), level of independence (p < 0.0001) and environ-
mental health (p = 0.005).  
• Being female, being 
heterosexual, having low 
socioeconomic and educational 
status, having acquired HIV 
through an injection route, and 
living more years with HIV 
were related to poorer HRQoL.  
Venturini [47] 
n = 943  






• Patients with CD4 count < 200 cells/µL 2 com-
pared with > 500 cells/µL had a lower score in the EQ-
VAS (p = 0.02)  
• Older age, HCV coinfec-
tion, education level and hospi-
talization due to HIV were 
associated with a low percep-





n = 1000  







• CD4 deficiency and number of self-reported side 
effects were negatively associated with PHS (p < 0.0001 
for both variables in both random and joint effect mod-
els) and MHS (p = 0.021 in random effect model and p = 
0.018 in the joint model for CD4 count and p < 0.0001 in 
both models for side effects) over 5 years after HAART 
initiation.  
• Low age, high educa-
tion level and being MSM were 
associated with better PHS.  
• Having a stable partner 
and HIV infection not acquired 
through the injection route 
were associated with higher 
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• Clinical stage of AIDS (p < 0.0001 for both ran-
dom effects and joint model and HCV coinfection were 
negative predictors of PHS (p = 0.047 for both models).  
MHS.  
• Comfortable housing 
conditions were positively 




n = 265 








• Patients who started HAART with <200 CD4 
cells/µL 2 had significantly worse baseline PHS than 
those who started with >200 CD4 cells/µL. 
• These patients showed a significantly greater 
improvement in PHS than those who started HAART 
with higher CD4 count (>200 cells/µL) 
 
Anis [54]  
(OPTIMA 
clinical trial) 
n = 368 










• ADEs and SAEs 2 had significant negative im-
pacts on HRQoL in the multivariate linear regression 
model. ADEs had a more persistent effect on HRQoL 
than SAEs, with a larger magnitude of effect across all 
instruments.  
• Increasing CD4 count was significantly associat-
ed with increasing HRQoL scores (p < 0.01 for PHS and 
MHS). Improvements in HIV-VL had significant posi-
tive impacts on HRQoL, although the magnitude was 
smaller than that of CD4 increase (p < 0.05 for PHS, p < 




n = 636 






• Significant indicators of worse PHS were lower 
CD4 counts 2, taking OI medications (p < 0.05), increas-
ing number of HIV-related symptoms (p < 0.0001) and 
non-AIDS comorbidities (p < 0.0001).  
• An AIDS diagnosis by itself was no longer 
significantly related to PHS after controlling for varia-
bles such as HIV symptoms and the current use of OI 
medications. 
• Older age, lower socio-
economic status, fewer male 
sexual partners, and no alcohol 
drinking were significant 
predictors of lower PHS scores. 
• Use of recreational 
drugs, interruption of ART in 
the past six months, and low 
social support were significant 
predictors of poor MHS. 
Emuren [56] 






• CD4 count < 200 cells/µL 2 predicted both PHS (p 
= 0.0008) and MHS (p = 0.0003).  
• Medical comorbidities (p < .0001), and ADE (p < 
0.0001) were also significant predictors of PHS. Patients 
with medical comorbidities experienced a yearly im-
provement in PHS. 
• Ageing led to a longitu-
dinal reduction in PHS.  
• Mental comorbidities 
were associated with both PHS 
and MHS. 
ADE: AIDS-defining event; EQ-5D: EuroQol 5-dimension quality of life instrument; EQ-5D-3L: EuroQol 5-dimension-3-
level quality of life instrument; HAART: highly active antiretroviral therapy; HCV: hepatitis C virus; HIV-VL: HIV viral 
load; HRQoL: health-related quality of life; MHS: mental health status; MOS-HIV-30: Medical Outcomes Study HIV 
Health Survey; MSM: men who have sex with men; OI: opportunistic infections; PHS: physical health status; SAE: seri-
ous adverse event; SD: standard deviation; SF-12: 12-Item Short-Form Health Survey; SF-36: 36-Item Short Form Health 
Survey; SF-6D: 6-Dimension Short Form Health Survey; VAS: visual analogue scale; WHOQOL-HIV-BREF: World 
Health Organization quality of life survey for HIV patients. Source of biological markers (CD4 cell count, viral load): 1 
patient self-reported, 2 clinical records. 
4. Discussion and Conclusions 
Despite the efficacy and safety of current cART, PWHIV presenting for care with 
AHD or who progress to AIDS are at higher risk of mortality by new ADEs or NADEs. 
Longitudinal cohort studies and meta-analyses performed during the cART era demon-
strate that AHD is associated with a higher risk of developing ADC and NADC, espe-
cially NADCI. Traditional cardiovascular risk factors, exposure to some antiretroviral 
drugs, and persistent HIV viremia are associated with CVD in PWHIV. However, data 
from cohort studies suggest that AHD could be associated with stroke, CVD, and related 
mortality. Patients with previous cytomegalovirus end-organ disease or lower nadir 
CD4 are at risk of developing ischemic strokes. AHD also leads to worse HRQoL. Most 
of the studies about HRQoL presented in this review are cross-sectional studies. Unfor-
tunately, longitudinal studies evaluating the quality of life in patients previously diag-
nosed with AHD are scarce. Of those presented in this review, most include a large 
number of patients, strengthening the results. These studies agree that lower CD4 and 
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previous AIDS diagnosis are associated with lower HRQoL scores, regardless of the 
questionnaire used or other known variables associated with worse HRQoL. We need 
more longitudinal studies that analyze the HRQoL for longer periods of time after an 
AHD diagnosis. 
Antiretroviral Treatment guidelines from the World Health Organization (WHO) 
[57] and from the British HIV Association (BHIVA) [58] consider the AHD as a special 
issue, but both guidelines focus their interest on the treatment and prevention of oppor-
tunist diseases. Our study highlights the need to define AHD as a special state in the 
spectrum of HIV disease. The high incidence of NADEs and mortality found in AHD pa-
tients could be lowered with interventions on traditional risk factors; hence, the im-
portance of screening for risk factors, improving prevention, and creating sustainable 
care models to implement these interventions during follow-up. We need more longitu-
dinal studies that analyze the HRQoL for longer periods of time after an AHD diagnosis. 
In our opinion, HIV guidelines should consider AHD patients as a special population 
whose needs are different from PWHIV who present for care soon after HIV infection. 
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